EUVIMEDEUVIMED entdecken
Crossref

Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors

Junjie Zhang, Benjin Liu, Ruyue Ren, Shanshan Song, Xubin Bao, Xiajuan Huan, Hongrui Li, Jiahao Xu, Ting Yu, Ruifeng Wang, Ze-Hong Miao, Bing Xiong iD und 2 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Junjie Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. Chi…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Morpholines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Strategic Priority Research Program of the Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ubiquitin-specific protease 1 (USP1), a well-known member of the deubiquitinating enzymes, serves as a key regulator in DNA damage repair (DDR) processes. Herein, we utilized ring-opening and cyclization strategies based on KSQ-4279 to design a novel series of USP1 inhibitors featuring a morpholine scaffold. Notably, compound 38-P2 exhibited a more potent enzymatic and cellular inhibition activity compared to KSQ-4279. Mechanistically, 38-P2 was characterized as a selective, reversible, and noncompetitive USP1 inhibitor. 38-P2 efficiently activated the DDR pathway, induced cell cycle arrest and cell apoptosis, and inhibited cell survival. Importantly, it enhanced the sensitivity of olaparib-resistant cells to olaparib and showed a synergetic effect with andrographolide in BRCA-proficient cancer cells. Furthermore, 38-P2 had favorable pharmacokinetic profiles and good safety properties in vitro and in vivo. In the MDA-MB-436 xenograft model, 38-P2 displayed significant, dose-dependent antitumor efficacy. Overall, these findings indicate that 38-P2 is a promising lead compound for further drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMorpholinesAnimalsFemaleHumansMiceApoptosisCell Line, TumorCell ProliferationDrug DiscoveryEnzyme InhibitorsMice, NudeStructure-Activity RelationshipUbiquitin ThiolesteraseXenograft Model Antitumor AssaysHeterocyclic Compounds, 2-RingPyrimidinesUbiquitin-Specific Proteases

Substanzen

Antineoplastic AgentsEnzyme InhibitorsMorpholinesUbiquitin ThiolesteraseHeterocyclic Compounds, 2-RingPyrimidinesUSP1 protein, humanUbiquitin-Specific Proteases

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, P. R. China.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China.
  • University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China.
  • State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • School of Pharmacy, Shanxi Medical University, Taiyuan 030001, China.

ORCID-Profile: Bing Xiong, Tongchao Liu

Förderung

  • National Natural Science Foundation of China
  • Strategic Priority Research Program of the Chinese Academy of Sciences

Zitieren

APA

Zhang, J., Liu, B., Ren, R., Song, S., Bao, X., Huan, X., Li, H., Xu, J., Yu, T., Wang, R., Miao, Z. H., Xiong, B., He, J., & Liu, T. (2025). Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02792

Vancouver

Zhang J, Liu B, Ren R, Song S, Bao X, Huan X, et al. Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02792

BibTeX
@article{Zhang2025,
  author = {Zhang, Junjie and Liu, Benjin and Ren, Ruyue and Song, Shanshan and Bao, Xubin and Huan, Xiajuan and Li, Hongrui and Xu, Jiahao and Yu, Ting and Wang, Ruifeng and Miao, Ze-Hong and Xiong, Bing and He, Jinxue and Liu, Tongchao},
  title = {Discovery and Optimization of a Series of Novel Morpholine-Containing USP1 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02792}
}
Kostenlos starten →